Abstracts tagged "obesity"

Abstract Number: 1694 • ACR Convergence 2025
Obesity Exacerbates Autoimmunity by Dysregulating B Cell Behavior
Munir Akkaya, Sohret Gokcek, Billur Akkaya and Wael Jarjour, The Ohio State University, Columbus, OH
Background/Purpose: Obesity is a major public health concern in the United States, affecting over 100 million individuals. While its detrimental effects on multiple organ systems…
Abstract Number: 1646 • ACR Convergence 2025
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Queeneth Edwards¹, Chukwuemelie Okeke², Justin Riley³, Ufuoma Mamoh⁴ and Chekwube Obianyo⁵, ¹Georgia Southern University, Statesboro, GA, ²Maimonides Medical Center, Brooklyn, NY, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁵Georgia Southern University, statesboro
Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
Abstract Number: 1383 • ACR Convergence 2025
Obesity in Primary Sjogren’s Disease
Gabriela Hernandez-Molina¹, Donaji Gómez-Velasco², Ariel Garcia-Torralba², Carlos Aguilar-Salinas² and Ivette Cruz-Bautista², ¹Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Obesity is an excessive fat accumulation that presents a risk to health. Little is known about the relationship between obesity and Sjögren’s disease (SjD).…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 2259 • ACR Convergence 2024
Effects of Anti-Obesity Medications in RA Patients
Elizabeth Dente¹, David Kellner², Vincent Tran², Travis Welsh², Victor Tran³, Angshuman Saha¹, Jenny Brook¹, David Elashoff⁴ and Veena Ranganath², ¹UCLA, Los Angeles, ²UCLA, Los Angeles, CA, ³UCLA, Costa Mesa, CA, ⁴UCLA Department of Medicine Statistics Core, Los Angeles
Background/Purpose: It is standard practice to advocate for weight loss in patients with rheumatoid arthritis (RA) and obesity. Obesity and rheumatoid arthritis are both independently…
Abstract Number: 2350 • ACR Convergence 2024
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Mikkel Ostergaard³, Bente Glintborg⁴, Signe Møller-Bisgaard⁵, Marion Pons⁶, Jette Heberg⁷, Sara Nysom Christiansen⁸, Simon Horskjær Rasmussen⁶, Anne Gitte Loft⁹, Isabel Castrejon¹⁰, Lucia Otero-Varela¹¹, Jakub Závada¹², Karel Pavelka¹², Jarno Rutanen¹³, Laura Kuusalo¹⁴, Michael Nissen¹⁵, Ziga Rotar¹⁶, Katja Perdan-Pikmajer¹⁶, Miguel Bernardes¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Irene E. van der Horst-Bruinsma¹⁹, Karin Laas²⁰, Brigitte Michelsen²¹, Catalin Codreanu²², Daniela DiGuiseppe²³, Burkhard Moeller²⁴, Gökçe Kenar²⁵, Merete Hetland²⁶ and Lykke Oernbjerg², ¹Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁵Rigshospitalet, Glostrup and Slagelse Hospital, Glostrup, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Rigshospitalet Glostrup, København V, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ⁹Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹Spanish Society of Rheumatology, Madrid, Spain, ¹²Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹³Tampere University Hospital, Tampere, Finland, ¹⁴University of Turku and Turku University Hospital, Turku, Finland, ¹⁵Geneva University Hospital, Geneva, Switzerland, ¹⁶University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁷São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰East-Tallinn Central Hospital, Tallinn, Estonia, ²¹Rigshospitalet, Glostrup and Diakonhjemmet Hospital and Sørlandet Hospital, Kristiansand, Norway, ²²University of Medicine and Pharmacy, Bucharest, Romania, ²³Karolinska Institutet, Stockholm, ²⁴Inselspital - University Hospital Bern, Bern, Switzerland, ²⁵Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…
Abstract Number: 2386 • ACR Convergence 2024
Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Alexandra Reese¹, Chandana Keshavamurthy², Sneha Centala¹, Samantha Ahrens¹, Shivani Shah², Douglas Reeves², William Davis³, Robert Quinet⁴, Jerald Zakem¹, Qingli Wu¹, Kimmy Tran¹, Teresa Leeth⁵, Daniyal Nadeem⁶, Sarwat Umer⁷, Samina Hayat⁵ and Xin Zhang¹, ¹Ochsner Health, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health, River Ridge, LA, ⁵Louisiana State University Shreveport, Shreveport, LA, ⁶LSU Shreveport, Shreveport, ⁷LSU HEALTH SHREVEPORT, SHREVEPORT, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by autoantibodies and disruption of multiple organs due to immunomodulatory dysfunction. Obesity is a…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Joshua Baker¹, George Reed², Geoffrey Thiele³, Dimitrios Pappas⁴, christina Charles-Schoeman⁵, Monica Guma⁶, Leslie Harrold⁷, Jeffrey Curtis⁸ and Joel Kremer⁹, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴CorEvitas, New York, NY, ⁵UCLA Medical Center, Santa Monica, CA, ⁶UCSD, La Jolla, CA, ⁷CorEvitas, Northborough, MA, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Michael Nevitt⁴, C.E. Lewis⁵, James Torner⁶ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴UCSF, Orinda, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…
Abstract Number: 1050 • ACR Convergence 2024
The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Daniel Betensky¹, Jeffrey Katz¹, Catherine Yang², David Hunter³, Jamie Collins¹, Candace Feldman¹, Karen Smith¹, Stephen Messier⁴, Jason Kim⁵, Faith Selzer⁶ and Elena Losina¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁴Wake Forest University, Winston Salem, NC, ⁵Arthritis Foundation, Atlanta, GA, ⁶Brigham and Women's Hospital, Amesbury, MA
Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
Abstract Number: 1187 • ACR Convergence 2024
Association of Depressive Symptoms and Multiple Joint Osteoarthritis with Pain Outcomes in the WE-CAN Trial
Natalie Allcott¹, Stephen Messier², Shannon Mihalko², Jeffrey Katz³, Paul DeVita⁴, David Hunter⁵, Sara Quandt⁶, Carolina Alvarez⁷, Leigh Callahan⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Wake Forest University, Winston Salem, NC, ³Brigham and Women's Hospital, Brookline, MA, ⁴Eastern Carolina University, Greenville, ⁵Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁶Wake Forest University, Winston-Salem, ⁷University of North Carolina at Chapel Hill, Miami, FL, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: The Weight-loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) trial was a community-based, pragmatic randomized clinical trial in men and women…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].